Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.98 |
| ▸ | GAA | P10253 | 5/20 | 0.98 |
| ▸ | POLB | P06746 | 4/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | APEX1 | P27695 | 2/20 | 0.98 |
| ▸ | RECQL | P46063 | 1/20 | 0.87 |
| ▸ | P4HB | P07237 | 6/20 | 0.87 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.87 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.87 |
| ▸ | ALPL | P05186 | 2/20 | 0.87 |
| ▸ | ALPI | P09923 | 2/20 | 0.87 |
| ▸ | CA12 | O43570 | 2/20 | 0.87 |
| ▸ | CA2 | P00918 | 2/20 | 0.87 |
| ▸ | CA4 | P22748 | 2/20 | 0.87 |
| ▸ | CA7 | P43166 | 2/20 | 0.87 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.87 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.87 |
| ▸ | KDM1A | O60341 | 1/20 | 0.87 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.87 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724190 | 1.00 | KDM4E (0.98) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL20801876 | 1.00 | KDM4E (0.98) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL20801877 | 1.00 | KDM4E (0.98) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL27617329 | 1.00 | KDM4E (0.98) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL23070285 | 0.99 | KDM4E (1.00) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL29897592 | 0.99 | KDM4E (1.00) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL30637437 | 0.96 | KDM4E (0.91) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL20801984 | 0.95 | P4HB (0.90) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL30772282 | 0.95 | P4HB (0.90) | KDM4EGAAPOLBMAPTAPEX1 | |
| SCHEMBL31720515 | 0.95 | P4HB (0.90) | KDM4EGAAPOLBMAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765128-B2 | Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2020-09-08 | — | — | US | disclosed |
| US-20190075823-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765128-B2 | Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients | GPX1, GSTP1, GSS | KDM4E 4058/4885GAA 92/4885POLB 2591/4885 |
| US-20190075823-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS | GPX1, GSTP1, PON1 | KDM4E 4169/4885GAA 144/4885POLB 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.